Chembio Diagnostics, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its SURE CHECK HIV 1/2 and HIV 1/2 STAT-PAK rapid test Pre-Market Applications (PMAs). The approved PMAs allow Chembio to market its rapid HIV tests to clinical laboratories and hospitals in the United States. FDA approval also allows Chembio to further expand its international marketing efforts into countries that require regulatory approval in the manufacturer's country of domicile.
Genetic Engineering News
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Devicemakers Pay $9.5 Million for Selling Uncleared Products
The FDA hit Instrumed with a warning letter in 2014.
Federal Circuit Won’t Rehear Purdue Pharma’s OxyContin Patent Claims
The U.S. Court of Appeals for the Federal Circuit turned down Purdue’s appeal and upheld the PTAB ruling.
FDAnews Device Daily Bulletin
CHEMBIO RECEIVES FDA APPROVAL FOR ITS RAPID HIV TESTS; COMPANY EXPECTS NEW MARKET OPPORTUNITIES AND REVENUE GROWTH
May 31, 2006
